PUBLIC COMPANY
save$SNYSanofi
$SNY45.83+1.91%Paris, FRupdated 5h ago
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in the Forbes Global 2000 was 89.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval433 co-mentions · 217 sources
- company$SNYNFSanofi234 co-mentions · 225 sources
- drugRIFADIN233 co-mentions · 117 sources
- tagSmall Molecule168 co-mentions · 168 sources
- drugrifampin117 co-mentions · 117 sources
- drugRIFATER50 co-mentions · 25 sources
- drugPRIMAQUINE36 co-mentions · 18 sources
- drugrifapentine34 co-mentions · 17 sources
pipeline
27
marketed
1
phase 3
9
catalysts ytd
6
approvals ytd
1
recalls ytd
0
Pipeline(27)
view full pipeline →pipeline depth27 products
1Preclinical2Phase 112Phase 29Phase 31Marketed2pre_registration
Marketed
rilzabrutinib
Acquired (Autoimmune) Hemolytic Anemia
Tyrosine-protein kinase BTK
Phase 3Coronavirus Disease 2019 (COVID-19) vaccine
Coronavirus Disease 2019 (COVID-19)
Spike glycoprotein
Phase 3Fluzone QIV HD
Unspecified Influenza Virus Infections
Phase 3SP-0218
Yellow Fever
Phase 3VerorabVax
Rabies
Phase 3avalglucosidase alfa
Pompe Disease
Phase 3frexalimab
Relapsing Remitting Multiple Sclerosis (RRMS)
Phase 3gusacitinib hydrochloride
Hand Dermatitis
Phase 3riliprubart
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 3venglustat malate
Fabry Disease
Phase 2IIV-HD + rC19
Coronavirus Disease 2019 (COVID-19)
Phase 2RIV3 + rC19
Coronavirus Disease 2019 (COVID-19)
Upcoming
Recent(90d)
view all catalysts →Active trials
- N/AEarly Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
- phase3A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- phase1First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
- —A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
- phase3Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
- phase3A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- phase3An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
- —An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia
🐶 Hiring Signal
next earnings Oct 30, 2026
Where Sanofi is staffing up — a leading indicator of pipeline and commercial priorities.
News
- 11 companies hiring in New JerseyLooking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data. Here are 11 companies with open roles.biospace · 12h ago
- STAT+: Doritos as farm-to-table snacks? Big Food, under duress, gets creativeDoritos in the classic nacho cheese flavor have 27 ingredients, including not just familiar ones but also a number of additives and preservatives.stat · 1d ago
- STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisitionSanofi, one of the Massachusetts' largest pharmaceutical employers, will lay off more than 200 workers there a year after acquiring Blueprint Medicines.stat · 2d ago
- Regeneron ends eye disease trial for anti-CD3 antibody following safety reviewRegeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.fiercebiotech · 2d ago
- STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and moreThe FDA approved a Bristol oral treatment for advanced multiple myeloma, marking the debut of a new class of medicine for the blood cancerstat · 5d ago
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersThe FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.biopharma_dive · 5d ago
- STAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticismA lab that tussled with regulators over impurities found in widely used medicines has accused U.S. Pharmacopeia of making false and misleading remarks about its methods.stat · 5d ago
- STAT+: Commure terminates payments under its customer referral programs tied to AI productsCommure, which develops and sells AI products to clinics, has terminated a program that paid for referrals to new customers.stat · 6d ago
- STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and moreSeven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 eachstat · 6d ago
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.fiercebiotech · 6d ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that